Luminescent properties of blood in oncological diseases: searching for the first tumour marker
Elena V. Naumova1, Ilya V. Volodyaev2; 1 Rzhanov Institute of Semiconductor Physics SB RAS, Novosibirsk, Russia; 2 Moscow State University, Moscow. Russia,
Abstract
In the 1920s–1930s it was demonstrated that the blood of healthy individuals have endogenous ultra-weak UV luminescence (mitogenetic radiation by terminology of that time), whereas in case of malignant neoplasms of any localization at the earliest stages a peptide (or a group of similar peptides) appears in the blood that quenches this UV luminescence [A.G. Gurwitsch et al. Uchenije O Rakovom Tushitele: Teorija I Klinika [The Teaching of the Cancer Quencher: Theory and Clinics] (in Russian). Moscow: USSR Academy of Medical Sciences Press, 1947, 100 p.].
In the 1940s, several leading oncology clinics in the USSR confirmed the high sensitivity and specificity (>95%) of this cancer marker, that was named the "cancer quencher." Although clinical studies demonstrated its potential for early cancer diagnosis and therapy monitoring, further research was discontinued [I.V. Volodyaev et al. Ultra-weak Photon Emission from Biological Systems: Endogenous Biophotonics and Intrinsic Bioluminescence, Springer-Nature, 2023, Chapters 1, 23].
This review examines the key results on "cancer quencher" and some of the later studies on the specific luminescent properties of blood of cancer patients (like the quenching of serum photochemiluminescence in oncology patients [Kulikov, V.Yu. Diagnosticheskiye Vozmozhnosti Metoda Kvantometrii v Klinike Vnutrennikh Bolezney [Diagnostic Potential of Quantometry in Internal Medicine] (In Russian), PhD Thesis, Novosibirsk, 1970, 225 pp.] etc., and their possible relevance to the "cancer quencher."
Speaker
Elena V. Naumova
Rzhanov Institute of Semiconductor Physics SB RAS, Novosibirsk
Russia
Discussion
Ask question
